Issues that may determine the outcome of antipsychotic trials: Industry sponsorship and extrapyramidal side effect

Neuropsychopharmacology

Volumn 33, Issue 5, 2008, Pages 971-975

  Davis, John M ^a,b   Chen, Nancy ^a   Glick, Ira D ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Bias; Meta analysis; Pharmaceutical industry

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; EXTRAPYRAMIDAL SYMPTOM; FUNDING; HUMAN; INTERNAL BIAS; META ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIAS (EPIDEMIOLOGY); BRIEF PSYCHIATRIC RATING SCALE; DATABASES, FACTUAL; DRUG INDUSTRY; HUMANS; MENTAL DISORDERS; META-ANALYSIS AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 40549095372     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301493     Document Type: Article

References (22)

1. Bodenheimer T (2000). Uneasy alliance - clinical investigators and the pharmaceutical industry (see comment). N Engl J Med 342: 1539-1544.
2. Borenstein M, Hedges L, Higgins J, Rothstein H (2005). Comprehensive Meta-Analysis, version 2. Biostat: Englewood, NJ.
3. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT (1998). Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155: 751-760.
4. Conley RR, Mahmoud R (2001). A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158: 765-774.
5. Davis JM, Chen N (2001). The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 62: 757-771.
6. Davis JM, Chen N (2002). Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 28: 43-61.
7. Davis JM, Chen N (2004). Dose-response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24: 192-208.
8. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
9. Geddes J, Freemantle N, Harrison P, Bebbington P (2000). The National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia systematic overview and meta-regression analysis. Br Med J 321: 1371-1376.
10. Guy W (1976). Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology. In: US Department of Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health: Rockville MD, pp 218-222.
11. Hedges LV, Olkin I (1985). Statistical Methods for Meta-Analysis. Academic Press: Orlando, FL.
12. Heres S, Davis JM, Maino K, Jetzinger E, Kissling W, Leucht S (2006). Why olanzapine beats risperidone, risperidone beats quetiapine and quetiapine beats olanzapine again: an analysis of head-to-head studies on second-generation antipsychotics. Am J Psychiatry 163: 185-194.
13. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. The Clozaril Collaborative Study Group. Arch Gen Psychiatry 45: 789-796.
14. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
15. Klein DF, Davis JM (1969). Diagnosis and Drug Treatment of Psychiatric Disorders. Williams & Wilkins: Baltimore, MD.
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
17. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials (erratum appears in J Clin Psychiatry 1998;59(4):200). J Clin Psychiatry 58: 538-546.
18. Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F et al (2004). An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 25: 598-612.
19. Overall J, Gorham D (1962). The Brief Psychiatric Rating Scale. Psychol Rep 10: 799-812.
20. Rosenberg MS, Adams DC, Gureveitch J (2000). MetaWin: Statistical Software for Meta-Analysis, Version 2.0 edition. Sinauer Associates: Sunderland, MA.
21. Rosenheck RA (2005). Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 56: 85-92.
22. Wang MC, Bushman BJ (1999). Integrating Results Through Meta-Analytic Review Using SAS Software. SAS Institute Inc: Cary, NC.